Whitehawk Therapeutics
Open
$4.03
Prev. Close
$4.03
High
$4.03
Low
$4.01
Market Snapshot
$190.4M
-9.2
-2.36
$25.98M
23
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 23 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
emptyResult
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 23 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Recently from Cashu
Whitehawk Therapeutics Advances Antibody-Drug Conjugate Research at AACR Annual Meeting 2026
Whitehawk Therapeutics Showcases Breakthroughs in Antibody-Drug Conjugate Development at AACR Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics firm, confirms its participation in t…
Whitehawk Therapeutics Showcases Innovative ADCs at Upcoming AACR Annual Meeting 2026
Whitehawk Therapeutics Advances Oncology Research with Upcoming AACR Presentations Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company, is poised to make significant contribut…
Whitehawk Therapeutics Advances Cancer Treatment with HWK-007 and HWK-016 Antibody-Drug Conjugates
Whitehawk Therapeutics Advances Antibody-Drug Conjugate Programs for Cancer Treatment Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company, makes significant strides in its ant…
Whitehawk Therapeutics Appoints Dr. Margaret Dugan as CMO to Advance Oncology Development
Whitehawk Therapeutics Strengthens Leadership with Appointment of Dr. Margaret Dugan as CMO Whitehawk Therapeutics, Inc. makes a significant stride in its oncology therapeutic development by appointin…